TRCT
AVTX icon

Tower Research Capital (TRC)’s Avalo Therapeutics AVTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,737
Closed -$159K – 5127
2025
Q4 		$159K Buy
8,737
+8,711
+33,504% +$147K ﹤0.01% 1616
2025
Q3 		$330 Buy
+26
New +$224 ﹤0.01% 5029
2025
Q1 		– Sell
-4,130
Closed -$30.7K – 5189
2024
Q4 		$30.7K Buy
4,130
+3,754
+998% +$40.1K ﹤0.01% 2888
2024
Q3 		$3.57K Buy
+376
New +$3.88K ﹤0.01% 4818
2024
Q2 		– Sell
-1,640
Closed -$35.7K – 5682
2024
Q1 		$35.7K Sell
1,640
-126
-7% -$679 ﹤0.01% 2508
2023
Q4 		$16.1K Buy
1,766
+1,559
+753% +$35.1K ﹤0.01% 3796
2023
Q3 		$6.02K Buy
207
+148
+251% +$6.61K ﹤0.01% 4653
2023
Q2 		$5.04K Buy
59
+49
+490% +$33K ﹤0.01% 4871
2023
Q1 		$4K Buy
+10
New +$7.88K ﹤0.01% 5042
2022
Q4 		– Hold
0
– – – 5875
2022
Q3 		– Hold
0
– – – 6050
2022
Q2 		– Sell
-5
Closed -$11K – 6062
2022
Q1 		$11K Buy
5
+2
+67% +$5.02K ﹤0.01% 4142
2021
Q4 		$13K Hold
3
– – ﹤0.01% 4150
2021
Q3 		$18K Buy
3
+1
+50% +$8.11K ﹤0.01% 3802
2021
Q2 		$18K Sell
2
-2
-50% -$16.8K ﹤0.01% 3978
2021
Q1 		$33K Buy
4
+2
+100% +$18.9K ﹤0.01% 3478
2020
Q4 		$18K Sell
2
-9
-82% -$62.5K ﹤0.01% 3925
2020
Q3 		$75K Buy
11
+9
+450% +$67.6K ﹤0.01% 3350
2020
Q2 		$14K Sell
2
-1
-33% -$7.26K ﹤0.01% 3859
2020
Q1 		$20K Buy
+3
New +$31.7K ﹤0.01% 1705
2019
Q4 		– Hold
0
– – – 3017
2019
Q3 		– Sell
-1
Closed -$11.2K – 4076
2019
Q2 		$8K Hold
1
– – ﹤0.01% 2672
2019
Q1 		$18K Hold
1
– – ﹤0.01% 2316
2018
Q4 		$7K Sell
1
-1
-50% -$11.1K ﹤0.01% 2668
2018
Q3 		$24K Buy
+2
New +$26.2K ﹤0.01% 2209
2018
Q2 		– Hold
0
– – – 2993
2016
Q4 		– Hold
0
– -$2K – 3811
2016
Q3 		– Hold
0
– – – 3026
2016
Q2 		– Hold
0
– -$3K – 4412
2016
Q1 		– Hold
0
– – – 3045
2015
Q4 		– Hold
0
– – – 3388

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Tower Research Capital (TRC)'s AVTX Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 8,737 shares — an estimated $159K sold.

Tower Research Capital (TRC) first reported a position in AVTX in Q3 2018 and held it in 22 quarters. The position peaked at $159K in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 8,737 Avalo Therapeutics shares in Q1 2026, an estimated $159K.
  • Tower Research Capital (TRC) first reported a position in Avalo Therapeutics in Q3 2018 and held it in 22 quarters.
  • Tower Research Capital (TRC)'s Avalo Therapeutics position peaked at $159K in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.